Drug Profile
Research programme: therapeutic and diagnostic antibodies - Open Monoclonal Technology/Merck KGaA
Alternative Names: Antibody discovery programme - OMT/Merck KGaA; Therapeutic and diagnostic OmniRat monoclonal antibodies - Open Monoclonal Technology/Merck KGaALatest Information Update: 22 Feb 2019
Price :
$50
*
At a glance
- Originator Merck KGaA; Open Monoclonal Technology
- Developer Ligand Pharmaceuticals; Merck KGaA; Open Monoclonal Technology
- Class Monoclonal antibodies; Monoclonal antibody diagnostics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified